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Abstract Several indices have been suggested to express the bronchodilator response butthere is no agreementon
what is the ideal expression.The forced expiratory volumein1s (FEV1) wasmeasuredin190 patients of bronchial asthma
before and after inhalation of 200 mg salbutamol.Four di¡erent indices of bronchodilator responsewere calculated.The
changein FEV1wasexpressedas absolutevalue (DFEV1), as apercentageof initial FEVl (DFEVl % initial), as apercentageof
the predictednormalvalue (DFEVl % predicted) and as a percentage ofmaximumachievable reversibility, i.e. the di¡er-
ence between predicted and initial values (DFEV1% [predicted^initial]). A signi¢cant negative correlationwas observed
between DFEVl initial and initial FEV1% predicted (r = 0.33, Po0.0001) but not DFEV1and initial FEVl% predicted, or
between DFEV1% predicted and initial FEVl% predicted.The values of DFEV1% [predicted^initial] tended to reach to-
wards in¢nity as the initial FEVl% predicted approached 100%. DFEVl% predicted had similar sensitivity but greater
speci¢city than DFEVl% initial in detecting a true bronchodilator response. It was concluded that being dependent
on the initial value, DFEVl% initial was not an appropriate method to express the bronchodilator response. Although
all othermethods had limitations, DFEVl and DFEV1% predicted appeared to be better indices.r2002 Elsevier Science Ltd. All
rights reserved.
doi:10.1053/rmed.2002.1327, available online at http://www.idealibrary.comon
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Measurement of airway response to a bronchodilator is
one of the commonest tests performed in a pulmonary
function laboratory, both for the purposes of patient
management and research.The results of the test often
form thebasis of classi¢cation of airwaydisease (into ‘‘re-
versible’’ and ‘‘irreversible’’ airway obstruction), choice of
therapeutic regimen and assessment of prognosis and
are also used as an inclusion or exclusion criterion in re-
search studies on asthma or chronic obstructive pulmon-
ary disease (COPD).Themostwidely used test to assess
airway function is spirometry in which the maximal ex-
piratory £ow volume (MEFV) maneuver is used to mea-
sure the forced expiratory volume in 1s (FEVl). There is
no agreement over howbronchodilator response should
be expressed (1) and several methods have been pro-
posed. Most commonly, it is expressed as a percentage
increase in FEVl over the initial value.There is, however,
no consensus on how much increase should be consid-
ered as a positive test. A 12, 15 and 20% increase haveAccepted 22 January 2002.
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Apart from a lackof consensus onwhat constitutes a po-
sitive response, a major drawback of this method is that
the percentage increase is a function of the initial value
(5^7). Other expressions of bronchodilator response
have been evaluated in heterogenous groups of patients
with chronic air£ow limitation and it has been suggested
that relating the change in FEVl to predicted value may
be the more appropriate way (7,8). The present study
was carried out to compare four di¡erent methods of
expressing thebronchodilator response in awell-de¢ned
population of asthmatics.
MATERIALANDMETHODS
One hundred and ninety consecutive patients of bron-
chial asthma reporting to the outpatient clinic of theDe-
partment of Cardiorespiratory Physiology at the
Vallabhbhai Pate1 Chest Institute, Delhi, were included
in the study. Asthmawas diagnosed if therewas a history
of recurrent episodes of breathlessness and wheezing,
with or without cough and phlegm, with seasonal and
diurnal variations and identi¢able triggering factors.
Only nonsmokers were included to avoid any diagnostic
confusion or an added component of COPD. Acceptable
TABLE 1. Baseline characteristics of the patients
Males
(n= 117)
Females
(n = 73)
Age 35.5712.5 35.5712.8
FEV1% predicted 55.8721.8 58.6721.4
FEV1/FVCratio 53.5711.1 55.3710.7
Severityof airway
obstructiona
Mild 36(30.8%) 25 (34.2%)
Moderate 29(24.8%) 17 (23.3%)
Severe 52(44.4%) 31 (42.5%)
aDe¢ned according to ATSrecommendations [11].
FIG 1. Relationship between absolute increase in FEV1 (DFEV1)
and initial FEV1% predicted.
612 RESPIRATORYMEDICINEperformance of spirometry and an FEV1/FVCratio of less
than 70% were the essential inclusion criteria. Patients
with any other systemic diseasewere excluded. Further,
patientswho had taken an inhaledbronchodilator within
the past 12h or an oral bronchodilator within the past
24hwere excluded.
Spirometry was performed on a dry, rolling-seal spi-
rometer of theTransferTest C model lung function ma-
chine (P.K.Morgan,Kent,U.K.).Maximal expiratory £ow
volume (MFV) curves were obtained as per the ATS re-
commendations (9). Three acceptable and at least two
reproducible curves were obtained in each subject.The
highest value of the FEV1 was selected. After baseline
spirometry, 200mg (100 2mg) salbutamol (Asthalin^Ci-
pla Ltd.) was administered by the technician from a me-
tered-dose inhaler. It was given keeping it about 3 cm in
front of the open mouth. This was done for reasons of
hygiene as the same inhaler was used on several patients
and further because supervised administration gives si-
milar results whether the inhaler is placed outside the
open-mouth or within the closed lips, as reported by us
earlier (10). Spirometry was repeated after 20min.
Expression of bronchodilator response
Change in FEV1 (DFEV1) after administration of broncho-
dilator was recorded. Prediction equations for north In-
dian subjects were used to calculate percent-predicted
values. Response to bronchodilator was expressed in
the following ways:
(i) Absolute change, i.e. as absolute increase in FEV1
(DFEV1).
(ii) Absolute change as a percentage increase over initial
FEV1 (DFEVl % initial).
(iii) Absolute change as a percentage of the predicted
normal value (DFEVl% predicted).
(iv) Absolute change as a percentage of maximum
achievable reversibility, i.e. the di¡erence between
predicted and initial values (DFEVl% [predicted^
initial]).
Distribution of variables was analyzed using Kolmo-
gorov^Smirnov (KS) tests. If Po 0.05 were obtained, in-
dicating skeweddistributions, nonparametric testswere
used. For variables with normal distribution, parametric
tests were applied.
RESULTS
The baseline characteristics of the patients are shown in
Table 1 .The distributions of DFEVl% initial and DFEVl%
[predicted^initial] were skewed (KS test, Z = 1.79,
Po0.01 and Z = 5.08, Po0.00001, respectively) while
those of DFEV1 and DFEV1% predicted were normal
(Z = 1.31, P40.05 and Z = 1.20, P40.05, respectively).All distributions were unimodal. The mean 7SD
values for the four expressions were as follows: DFEV1%
initial (26.25719.52), DFEVl% [predicted^initial]
(46.387179.06),DFEV1 (in liters) (0.3570.24) andDFEVl%
predicted (13.4578.83). The range of responses were:
DFEV1% initial from 11.39 to 95.65; DFEVl% [pre-
dicted^initial], from1739.13 to1074.88;DFEV1 (in liters),
from0.09 to1.13; andDFEV1%predicted,2.88 to 41.78.
The relationships between initial FEVl% predicted and
the four expressions of bronchodilator response were
examined (Figs. 1^4). There was a signi¢cant negative
correlationbetweenDFEV1% initial and initial FEV1%pre-
dicted (Spearman r = 0.33, Po0.000l, Fig. 1), the re-
sponse values increasing with decreasing initial lung
function. The relationships between DFEV1 and initial
FEV1% predicted, andbetweenDFEV1% predicted and in-
itial FEV1% predicted were not signi¢cant (Pearson r =
0.13, P40.05, Fig. 2, and r = 0.12, P40.05, Fig. 3, respec-
tively). The values of DFEV1% [predicted^initial] tended
to reach towards in¢nity as the initial FEV1% predicted
approached100% (Fig. 4). No correlation was computed
because of the scatter.
FIG 2. Relationship between absolute change as a percentage
of initial FEV1 (DFEV1% initial) and initial FEV1% predicted.
FIG 3. Relationship between absolute change as a percentage
of the predicted normal value (DFEV1% predicted) and initial
FEV1% predicted.
FIG 4. Relationship between absolute change as a percentage
ofmaximumachievablereversibility, i.e. the di¡erencebetween
predicted and initial values (DFEV1% [predicted^initial]) and in-
itial FEV1%predicted.
EXPRESSIONOFBRONCHODILATORRESPONSE 613We evaluated the sensitivity and speci¢city of the re-
commended cut-o¡’s of DFEVl% initial and DFEV1% pre-
dicted to identify a true bronchodilator response, takenas aDFEVl of 0.2 l ormore.Out of the133 patients with a
DFEV1 of 0.2 l or more, a 12% cut-o¡ for DFEVl% initial
identi¢ed 124 true positives, giving a sensitivity of 0.93.
However, among the remaining 57whohadDFEVl of less
than 0.2 l, 38 had DFEV1% initial of greater than12%, the
high false-positive rate giving a speci¢city of 0.67.The 9%
cut-o¡ for DFEVl% predicted gave a sensitivity of 0.87,
identifying115 true positives and a speci¢city of 0.95 due
to only 3 false positives.
DISCUSSION
In thepresent study carried out in awell-de¢nedpopula-
tion of asthmatics comparing four methods of assessing
acute bronchodilator responsiveness, absolute change in
FEVl (DFEVl) and DFEVl % predicted were found to be
independent of the initial FEVl while DFEV1% initial, and
DFEVl % maximum achievable reversibility (predicted
minus initial) were not. As dependence on the initial va-
lue is a major disadvantage of DFEVl % initial, the com-
monly used expressions, DFEV1 and DFEV1% predicted
may appear to be superior for use in clinical and research
studies.
There is no gold standard to identify a truebronchodi-
lator response. A statistically valid way would be to de-
¢ne an increase greater than 1.65 times the intra-
individual coe⁄cient of variation for repeated measure-
ments (which corresponds with the 95% probability le-
vel) as signi¢cant.On this basis, the ATS has de¢ned an
increase in FEV1 of greater than 200ml as indicating a
true bronchodilator response (11). As it is independent
of the initial value and has the ability to identify a true
bronchodilator response, DFEV1 would appear to be a
suitable parameter to measure bronchodilator respon-
siveness. Its limitations are that subjects with di¡erent
initial values which cannot be compared, the values are
not corrected for determinants of lung size such as age,
sex and height and it does not indicate how far the post-
bronchodilator value is from the predicted value.
The almost universal use of DFEV1 % initial in clinical
practice and research is surprising considering its limita-
tions. Di¡erent criteria, ranging from 12 to 20% have
been suggested as thresholds for a positive response
(2^4). These criteria have been evolved either by com-
paring the responses in asthmatics with normal subjects
orwith thosewithCOPD.Both approaches are £awedas
normal subjects are bound to have a smaller bronchodi-
lator responsewhen expressed as percent increase over
baseline while it has been shown that no cut-o¡ can be
de¢ned to separate asthmatics from patients with
COPD (7,12,13).Being highly dependent on the initial FEVl
as shown in the present study and previously by others
(5^7), this method would yield higher values in subjects
with lower initial values.Thus, there appears to be little
justi¢cation for the ATS recommendation of adopting a
614 RESPIRATORYMEDICINE12% and a 200ml increase in FEV1 as the criterion for a
signi¢cant bronchodilator response.This would lead to a
bias against patients with high initial values as a 12% in-
crease would require an absolute increase much greater
than 200ml.
The other two indices of bronchodilator responsive-
ness examined in the present study took into account
the predicted values of FEV1.Compared to DFEV1% initi-
al, DFEV1% predictedwith a cut-o¡ of 9% as criterion for
a positive response (8) had almost similar sensitivity but
greater speci¢city to detect a true bronchodilator re-
sponse and was also independent of the initial FEV1.On
the other hand, DFEVl% [predicted^initial] tended to
reach towards in¢nity as the initial FEVl approached the
predicted values giving apparently absurd values. Other
workers have also commented on the usefulness of
DFEV1% predicted as an expression of bronchodilator re-
sponse (6,7).Relating the change in FEVl to thepredicted
value corrects it for factors determining lung size such as
age, sex and height. However, it does not give any infor-
mation on thepostbronchodilator severity of airway ob-
struction and subjectswith di¡erent initial values cannot
be compared.Further, relating the change in FEV1to the
predicted values presents other problems. It assumes
that the predicted values represent themaximum possi-
ble values. In the population, assuming a normal distribu-
tion, the predicted values represent only the 50th
percentile values. The maximum possible values would
therefore be greater than the predicted values for half
the population. If the initial FEV1 is already greater than
the predicted value, the expression DFEV1% [predicted^
initial] would yield a meaningless value.Use of personal
best FEV1 instead of the predicted value would circum-
vent this problem. However, establishing personal best
with certaintymay be a time-consuming process requir-
ing a follow-up and is not practical for acute response
studies. Therefore, expressions based on predicted va-
lues do not appear to be a satisfactory method to ex-
press the bronchodilator response. Brand et al. (7)
calculated standardized residuals as the di¡erence be-
tween predicted FEV1 and the patient’s FEV1 divided by
the residual standard deviation of the FEV1reference for-
mula and expressed the bronchodilator response as the
di¡erence between the standard residuals of post- and
prebronchodilator FEV1.Besides having aweakbut signif-
icant relationship with the initial FEV1, it has the same
disadvantages as other expressions that take into ac-
count the predicted values.
The ideal expression of bronchodilator response
should be independent of the initial FEV1, should be ableto identify a true response to the drug, correlate well
with clinical response, allow comparison of subjectswith
di¡erent baseline values and provide information on the
severity of postbronchodilator airways obstruction.
Thus, there appears to be no ‘‘ideal’’ method of expres-
sing bronchodilator response.None of the indices exam-
ined in the present paper meet all these requirements.
Although all indices had limitations, DFEV1 and DFEV1%
predicted may appear to be somewhat better expres-
sions. A similar suggestionwasmadeby Eliasson andDe-
graf (14).
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